SCHEMBL4122745

SCHEMBL4122745

CCc1cccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.66
MEN1 O00255 4/20 0.62
MAPT P10636 4/20 0.62
KMT2A Q03164 4/20 0.62
TP53 P04637 2/20 0.62
CASP3 P42574 1/20 0.62
HTT P42858 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
RAB9A P51151 5/20 0.59
NPC1 O15118 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
KDR P35968 1/20 0.56
MAPK14 Q16539 1/20 0.56
TNNI3K Q59H18 1/20 0.56
IDH1 O75874 1/20 0.56
HDAC3 O15379 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113151 0.86 EPHX2 (0.78) EPHX2MEN1MAPTKMT2ARAB9A
SCHEMBL4124694 0.85 MAPT (0.75) MEN1MAPTKMT2ATP53HTT
SCHEMBL4113495 0.85 EPHX2 (0.62) EPHX2MEN1MAPTKMT2ATP53
SCHEMBL26156260 0.84 EPHX2 (0.69) EPHX2MEN1MAPTKMT2ATP53
SCHEMBL4117508 0.84 MAPT (0.70) MEN1MAPTKMT2ATP53RAB9A
SCHEMBL4104388 0.83 SMN1; SMN2 (0.64) MEN1MAPTKMT2ATP53HTT
SCHEMBL4104375 0.83 RAB9A (0.71) MEN1MAPTKMT2ATP53HTT
SCHEMBL26154100 0.82 EPHX2 (0.71) EPHX2MEN1MAPTKMT2ATP53
SCHEMBL4105188 0.82 MEN1 (0.59) MEN1MAPTKMT2ATP53HTT
SCHEMBL4123129 0.82 KDR (0.59) EPHX2MEN1MAPTKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 EPHX2 2394/4885MEN1 3273/4885MAPT 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.